{"doi":"10.3324/haematol.2012.064337","title":"Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors","abstract":null,"journal":"Haematologica","year":2013,"id":597721,"datarank":0.5926865577872142,"base_score":3.9512437185814275,"endowment":3.9512437185814275,"self_citation_contribution":0.5926865577872142,"citation_network_contribution":0.0,"self_endowment_contribution":0.5926865577872142,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":51,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1531353,"name":"M. Breccia","orcid":null,"position":1,"is_corresponding":false},{"id":1531354,"name":"E. Abruzzese","orcid":null,"position":2,"is_corresponding":false},{"id":1531355,"name":"F. Castagnetti","orcid":null,"position":3,"is_corresponding":false},{"id":1531356,"name":"L. Luciano","orcid":null,"position":4,"is_corresponding":false},{"id":1531357,"name":"A. Gozzini","orcid":null,"position":5,"is_corresponding":false},{"id":1531358,"name":"M. Annunziata","orcid":null,"position":6,"is_corresponding":false},{"id":1531359,"name":"B. Martino","orcid":null,"position":7,"is_corresponding":false},{"id":1531360,"name":"F. Stagno","orcid":null,"position":8,"is_corresponding":false},{"id":1531361,"name":"F. Cavazzini","orcid":null,"position":9,"is_corresponding":false},{"id":1531362,"name":"M. Tiribelli","orcid":null,"position":10,"is_corresponding":false},{"id":1531363,"name":"G. Visani","orcid":null,"position":11,"is_corresponding":false},{"id":1531364,"name":"P. Pregno","orcid":null,"position":12,"is_corresponding":false},{"id":1531365,"name":"P. Musto","orcid":null,"position":13,"is_corresponding":false},{"id":1531366,"name":"C. Fava","orcid":null,"position":14,"is_corresponding":false},{"id":1531367,"name":"N. Sgherza","orcid":null,"position":15,"is_corresponding":false},{"id":1531368,"name":"F. Albano","orcid":null,"position":16,"is_corresponding":false},{"id":1531370,"name":"G. Rosti","orcid":null,"position":17,"is_corresponding":false},{"id":1531372,"name":"G. Alimena","orcid":null,"position":18,"is_corresponding":false},{"id":1531374,"name":"G. Specchia","orcid":null,"position":19,"is_corresponding":false},{"id":1531352,"name":"A. R. Rossi","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors","abstract":"There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative tyrosine kinase inhibitor therapy. Thirty-four patients failed to respond to nilotinib and were started on dasatinib as third-line tyrosine kinase inhibitor therapy while 48 patients were switched to nilotinib after dasatinib failure. Overall, we obtained a cytogenetic response in 32 of 82 patients and major molecular response in 13 patients; disease progression occurred in 12 patients. At last follow up, 70 patients (85.4%) were alive with a median overall survival of 46 months. Our results show that third-line tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients after failure of two prior sequential tyrosine kinase inhibitors may induce a response that, in some instances, could prolong overall survival and affect event-free survival.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22801965","pmcid":"PMC3659922","openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"other-oa","oa_locations":[{"url":"https://haematologica.org/article/download/6590/36630","host_type":"publisher"},{"url":"http://www.haematologica.org/content/98/3/399.long","host_type":"repository"},{"url":"http://www.haematologica.org/content/98/3/399.full.pdf+html","host_type":"repository"},{"url":"http://hdl.handle.net/11392/2333201","host_type":"repository"}],"fields_of_study":[],"mesh_terms":["Humans","Pyrimidines","Thiazoles","Protein Kinase Inhibitors","Treatment Outcome","Treatment Failure","Adult","Aged","Aged, 80 and over","Middle Aged","Female","Male","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Dasatinib"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T14:02:28.602461Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}